Trade Ultragenyx Pharmaceutical Inc - RARE CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.20 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023512% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.00129% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 44.41 |
| Open | 44.45 |
| 1-Year Change | -7.12% |
| Day's Range | 42.5 - 44.79 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 21, 2025 | 42.50 | -2.08 | -4.67% | 44.58 | 44.84 | 42.49 |
| Feb 20, 2025 | 44.41 | 0.25 | 0.57% | 44.16 | 44.72 | 43.95 |
| Feb 19, 2025 | 44.24 | 0.65 | 1.49% | 43.59 | 44.80 | 43.23 |
| Feb 18, 2025 | 43.58 | 0.88 | 2.06% | 42.70 | 44.55 | 42.55 |
| Feb 14, 2025 | 42.40 | -1.25 | -2.86% | 43.65 | 45.90 | 41.68 |
| Feb 13, 2025 | 43.47 | -0.03 | -0.07% | 43.50 | 43.55 | 42.86 |
| Feb 12, 2025 | 43.36 | 0.56 | 1.31% | 42.80 | 43.58 | 42.26 |
| Feb 11, 2025 | 43.50 | -0.60 | -1.36% | 44.10 | 44.48 | 43.38 |
| Feb 10, 2025 | 44.73 | -0.53 | -1.17% | 45.26 | 45.40 | 44.58 |
| Feb 7, 2025 | 45.30 | -0.08 | -0.18% | 45.38 | 45.92 | 44.93 |
| Feb 6, 2025 | 45.72 | 0.56 | 1.24% | 45.16 | 46.39 | 44.56 |
| Feb 5, 2025 | 45.32 | 1.19 | 2.70% | 44.13 | 45.50 | 44.13 |
| Feb 4, 2025 | 44.13 | 0.97 | 2.25% | 43.16 | 44.32 | 42.72 |
| Feb 3, 2025 | 43.37 | 1.62 | 3.88% | 41.75 | 44.01 | 41.61 |
| Jan 31, 2025 | 42.95 | -0.42 | -0.97% | 43.37 | 43.63 | 42.66 |
| Jan 30, 2025 | 43.36 | 0.70 | 1.64% | 42.66 | 43.77 | 42.17 |
| Jan 29, 2025 | 42.37 | 0.32 | 0.76% | 42.05 | 42.95 | 41.99 |
| Jan 28, 2025 | 42.43 | -0.84 | -1.94% | 43.27 | 43.34 | 42.32 |
| Jan 27, 2025 | 43.21 | 0.53 | 1.24% | 42.68 | 44.52 | 42.68 |
| Jan 24, 2025 | 44.00 | 0.52 | 1.20% | 43.48 | 45.14 | 43.48 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
Ultragenyx Company profile
About Ultragenyx Pharmaceutical Inc
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company, which is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company’s therapies and clinical-stage pipeline consist of four product categories, such as biologics, small molecules, gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) is for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO); Mepsevii (vestronidase alfa) is for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome; Dojolvi (triheptanoin) is for the treatment of long-chain fatty acid oxidation disorders or LC-FAOD, and Evkeeza (evinacumab) is for the treatment of homozygous familial hypercholesterolemia (HoFH). The Company' clinical product candidates include DTX401, DTX301, UX143, GTX-102, UX701 and UX053.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Ultragenyx Pharmaceutical Inc revenues increased 30% to $351.4M. Net loss increased from $186.6M to $454M. Revenues reflect Crysvita collaboration revenue in profit-share territory segment increase of 33% to $171.2M, Dojolvi segment increase from $13M to $39.6M, United States segment increase of 27% to $301.1M, others segment increase of 96% to $23.6M.
Equity composition
Common Stock, $0.001 Par, 01/14, Auth. 250M Shares., 29,061,871 issd,. Insiders owns approx. 19.82%.
| Industry: | Bio Therapeutic Drugs |
60 Leveroni Ct
NOVATO
CALIFORNIA 94949
US
News
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025
FARTCOIN price prediction: Third-party price target
Read our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:18, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com